CFO transition
VitaSpring Biomedical Co. Ltd. CFO transition: Jing-Zhou Chen to succeed Ssu-Chuan Lai
VitaSpring Biomedical Co. Ltd. reported in a Form 8-K filed September 10, 2026 that Jing-Zhou Chen will succeed Ssu-Chuan Lai as Chief Executive Officer, President, Chief Financial Officer, and Secretary, effective September 7, 2026.
In the filing's words
Effective at 11:57 p.m. Pacific Time on September 7, 2026, Dr. Ssu-Chuan Lai, as the sole director then in office, appointed Jing-Zhou Chen as the Company’s Chief Executive Officer, President, Chief Financial Officer, and Secretary, to serve at the pleasure of the Board and until his successor is duly appointed and qualified, or until his earlier death, resignation or removal.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | VitaSpring Biomedical Co. Ltd. (VSBC) |
|---|---|
| Event | Transition |
| Incoming | Jing-Zhou Chen |
| Outgoing | Ssu-Chuan Lai |
| Title in the filing | Chief Executive Officer, President, Chief Financial Officer, and Secretary |
| Effective | September 7, 2026 |
| 8-K filed | September 10, 2026 |
| Internal promotion | No |
| Prior role (per filing) | founder and Chief Executive Officer, Dream Born Co., Ltd. |
| SEC CIK | 0001697884 |
VITASPRING BIOMEDICAL CO. LTD. reported this change in a Form 8-K, Item 5.02, filed September 10, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Jing-Zhou Chen? Send a correction with the primary source.